(KRYS) Krystal Biotech, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(KRYS) Krystal Biotech, Inc. Complete Analysis Pack
Krystal Biotech Business Model Canvas: Strategy at a Glance
Unlock the full strategic blueprint behind Krystal Biotech, Inc.'s business model. This concise Business Model Canvas shows how the company creates value, builds key partnerships, and supports growth in a competitive biotech market. Ideal for investors, analysts, and founders who want actionable insight—get the full version today.
Partnerships
Phase I/II and Phase III trial sites
Krystal Biotech, Inc. relies on multi-center dermatology, wound-care, and rare-disease trial sites to recruit, dose, and follow small orphan-disease cohorts across dispersed geographies; its B-VEC phase 3 program in dystrophic epidermolysis bullosa enrolled 31 patients. These sites also generate the efficacy and safety data needed for KB105 and KB301, where patient counts are too small for single-center studies to work.
Contract research organizations
Contract research organizations handle monitoring, data management, site coordination, and trial operations for Krystal Biotech, Inc.'s 1 approved therapy and multiple pipeline programs. This cuts internal workload and lets the Company run studies in parallel across sites, which is standard for a clinical-stage biotech with a broad pipeline.
Contract development and manufacturing organizations
Krystal Biotech, Inc. depends on contract development and manufacturing organizations (CMOs and CDMOs) for plasmid, vector, drug-product, and process manufacturing, which keeps GMP supply, scale-up, and batch release moving across clinical programs. For a redosable gene therapy platform, that outside manufacturing capacity is a core dependency, because any gap can delay supply to patients and slow program timelines.
Patient advocacy groups
Krystal Biotech, Inc. depends on patient advocacy groups for dystrophic epidermolysis bullosa and other rare skin diseases because these groups drive awareness, explain the 1-in-500,000 live-birth burden of DEB, and help reach small, hard-to-find trial pools. They also give patients and families disease education and peer support, which matters when many physicians have limited exposure to orphan indications.
- Boosts trial recruitment in ultra-rare disease
- Expands patient and caregiver education
- Connects families to support communities
Regulators and ethics boards
The FDA, IRBs, and other oversight bodies are key partners for Krystal Biotech, Inc. because they shape Phase I/II/III design, safety review, and approval steps for each asset. That matters across the pipeline and for commercial use, where VYJUVEK already sets the bar for regulatory alignment.
- FDA drives trial and launch path
- IRBs protect patient safety
- Alignment is needed for all assets
How Krystal Biotech Runs Rare-Disease Trials with Key Partners
Krystal Biotech, Inc. leans on CROs, CMOs/CDMOs, and rare-disease trial sites to run VYJUVEK and pipeline studies, including the 31-patient B-VEC phase 3 in dystrophic epidermolysis bullosa. Patient groups and regulators, led by the FDA and IRBs, help recruit small cohorts and keep safety, design, and approval on track.
| Partner | Role |
|---|---|
| CROs | Trial ops |
| CMOs/CDMOs | GMP supply |
| FDA/IRBs | Review and approval |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Krystal Biotech, Inc., outlining its gene-therapy strategy, customers, channels, and competitive advantages.
Customizable Excel Spreadsheet
Quickly spot how Krystal Biotech relieves patient pain points with a clear, editable business model snapshot.
Reference Sources
Provides a credible source trail for Krystal Biotech, Inc. that helps investors verify key claims and make faster, better-informed decisions.
Activities
B-VEC Phase III development
B-VEC, Krystal Biotech, Inc.'s lead asset and the only approved gene therapy for dystrophic epidermolysis bullosa in the U.S., drives the company’s most advanced clinical work. Key activities in Phase III focus on protocol execution, endpoint collection, safety monitoring, and data analysis, with 2025 cash-funded R&D supporting late-stage follow-through.
Pipeline advancement for KB105 and KB301
Krystal Biotech, Inc. is advancing KB105 in Phase I/II for autosomal recessive congenital ichthyosis and KB301 in Phase I/II for wrinkles and damaged-skin aesthetics, adding two early-stage programs to its pipeline. That matters because it broadens the company beyond Vyjuvek, its lead orphan-disease asset, and builds optionality across rare disease and dermatology.
Preclinical research for KB407 and KB104
Krystal Biotech, Inc. keeps preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome moving through candidate optimization, proof-of-concept studies, and toxicology support. These programs feed the next clinical wave, while the Company’s 2025 R&D spend of $121.8 million shows the scale of this pipeline build.
Gene-therapy platform development
Krystal Biotech’s key activity is building redosable gene therapies that use local delivery for hard-to-treat diseases. The platform is continuously improved across the pipeline, and it is anchored by 1 approved product, VYJUVEK, which validates the repeat-dosing model.
- Repeat dosing is a core design goal.
- Local delivery targets unmet needs.
- Platform upgrades run across pipeline work.
GMP, quality, and regulatory operations
Krystal Biotech’s GMP, quality, and regulatory work keeps Vyjuvek supply-ready: it must hold manufacturing quality, prove product comparability, and keep clinical lots ready while filing safety reports and CMC documents. This is the backbone for both development and commercialization, especially after the FDA approved Vyjuvek in 2023 as the first redosable gene therapy for dystrophic epidermolysis bullosa.
- Keep batch quality consistent
- File recurring safety updates
- Maintain CMC readiness
Krystal Biotech Keeps Investing in Vyjuvek and Pipeline Growth
Krystal Biotech, Inc.’s key activities center on running Vyjuvek manufacturing, quality, and regulatory work, while advancing its pipeline in Phase I/II and preclinical studies. In 2025, R&D spend was $121.8 million, showing continued investment in B-VEC, KB105, KB301, KB407, and KB104.
| Activity | 2025 data |
|---|---|
| R&D spend | $121.8 million |
| Lead approved asset | VYJUVEK for DEB |
Preview Before You Purchase
Business Model Canvas
This Krystal Biotech, Inc. Business Model Canvas preview is the actual document you’ll receive after purchase. It’s not a sample or mockup—what you see here is the same file, with the same structure and content. Once purchased, you’ll get full access to this exact, ready-to-use document.
Resources
Proprietary redosable gene-therapy platform
Krystal Biotech, Inc.’s redosable gene-therapy platform is its core technical asset: by FY2025 it had already powered 1 FDA-approved product, Vyjuvek, and multiple follow-on programs for skin and non-skin disease. That shared engine lowers development friction and helps Krystal build a differentiated pipeline versus standard biologics or one-time gene therapies.
Lead asset B-VEC and follow-on programs
Krystal Biotech’s key resources center on 5 named therapeutic assets: B-VEC, KB105, KB301, KB407, and KB104. B-VEC is the company’s first approved gene therapy for dystrophic epidermolysis bullosa, a rare disease seen in about 1 in 20,000 births, and the pipeline extends that scientific base into fibrosis and aesthetic dermatology.
Clinical data package
Krystal Biotech, Inc.’s clinical data package is a core intangible asset: Phase I/II and Phase III VYJUVEK studies supplied the efficacy, safety, and dose data needed for FDA review and payer support. In the pivotal GEM-3 trial, 67% of treated wounds fully closed at 6 months versus 22% on placebo, showing why clinical data is often a biotech’s most valuable near-term resource.
Scientific and regulatory talent
Scientific and regulatory talent is Krystal Biotech, Inc.’s core asset: researchers, clinicians, CMC specialists, and regulatory experts support one approved product, VYJUVEK, across discovery, manufacturing control, trial ops, and FDA filing work. For a small clinical-stage company, this bench is the main driver of speed, quality, and compliance.
- One approved therapy, VYJUVEK, anchors the team.
- Expertise spans discovery to submission planning.
- Small-company execution depends on this talent base.
Pittsburgh headquarters and operating infrastructure
Krystal Biotech, Inc. is based in Pittsburgh, Pennsylvania, and its headquarters anchor management, research coordination, finance, and corporate operations. That centralized setup supports a 1-product commercial base, VYJUVEK, while keeping oversight tight across its multi-program biotech pipeline.
Pittsburgh HQ keeps core functions in one place.
Central control helps manage 1 commercial product.
Supports coordination across multiple pipeline programs.
Krystal Biotech’s Gene-Therapy Platform Powers One Approved Drug and Five Programs
Key resources are Krystal Biotech, Inc.’s redosable HSV-1 gene-therapy platform, its 1 approved product VYJUVEK, and a pipeline of 5 named programs. The platform has already cleared FDA review in 1 rare disease and supports expansion into 4 other programs.
| Resource | FY2025 |
|---|---|
| Approved product | 1 |
| Named programs | 5 |
| Headquarters | Pittsburgh, PA |
Value Propositions
Redosable gene therapies
Krystal Biotech’s redosable gene therapies can be given more than once, unlike one-and-done gene replacement models, which matters in chronic diseases where symptoms keep coming back. Vyjuvek, its lead therapy, is approved for repeated weekly use in dystrophic epidermolysis bullosa, and Krystal reported 2025 revenue above $300 million, showing real demand for a repeat-dose model.
Local treatment for severe skin disease
For dystrophic epidermolysis bullosa, which affects about 1 in 500,000 births, Krystal Biotech targets the wound itself with skin-directed therapy, limiting systemic exposure in fragile-skin patients. This local approach fits severe orphan skin disease, where treatment options are few and even one approved therapy can change care.
B-VEC for dystrophic epidermolysis bullosa
B-VEC (Vyjuvek) is Krystal Biotech’s most advanced asset and the first FDA-approved gene therapy for dystrophic epidermolysis bullosa, a rare disease that affects about 1 in 20,000 births and drives chronic wounds, pain, and infection risk. Its value is a disease-specific treatment for a severely underserved patient pool.
Broad pipeline across rare and aesthetic dermatology
Krystal Biotech, Inc. turns one HSV-1 platform into multiple shots on goal: approved VYJUVEK for DEB plus programs in ARCI, Netherton syndrome, cystic fibrosis, and aesthetics. That breadth matters in 2025 because it spreads risk across rare-disease and consumer markets, while keeping R&D tied to one delivery base.
- One platform, many indications
- Rare disease plus aesthetics mix
- Less dependence on DEB alone
Potential repeat-use and chronic-care fit
Krystal Biotech, Inc.'s redosable VX-101 approach fits chronic skin diseases because patients can need repeated treatment, not a one-time fix. That matters in long-term care, where the goal is steady disease control and fewer flare-ups, and Vyjuvek is already approved as the first FDA gene therapy that can be reapplied as needed.
- Matches recurring treatment needs
- Supports long-term disease control
- Improves use in persistent conditions
Krystal Biotech’s Vyjuvek Proves Gene Therapy Can Scale
Krystal Biotech’s value proposition is a repeat-dose, skin-directed gene therapy platform that solves a real need in chronic rare disease. Vyjuvek is the first FDA-approved gene therapy for dystrophic epidermolysis bullosa, and 2025 revenue topped $300 million, proving payer and patient demand.
| Metric | Value |
|---|---|
| Lead asset | Vyjuvek |
| FDA status | First approved for DEB |
| 2025 revenue | Above $300 million |
| Disease focus | Chronic orphan skin disease |
Customer Relationships
Physician-led treatment support
Krystal Biotech’s physician-led model centers on dermatologists and wound-care specialists, who prescribe and monitor Vyjuvek for dystrophic epidermolysis bullosa, a rare disease seen in about 1 in 20,000 to 1 in 50,000 births. The company must give dosing, wound-care, and safety guidance, so the relationship stays high-touch and built around repeat follow-up.
Patient access and education
Krystal Biotech’s patient access model depends on strong disease education, logistics help, and clear therapy expectations, because VYJUVEK is used in a rare disease that was studied in 31 patients in its pivotal program. Specialty-center delivery makes onboarding and steady caregiver communication critical, so families know wound care steps, dosing timing, and follow-up needs.
Clinical-trial participant management
Krystal Biotech's clinical-trial participant management is built around small orphan-disease pools, where U.S. orphan status means fewer than 200,000 patients. That makes enrollment, informed consent, visit scheduling, and follow-up highly hands-on, and in trials with only dozens of participants, retention and complete data are critical to keep results usable.
Medical affairs engagement
Krystal Biotech, Inc. uses medical affairs to keep scientific dialogue open with experts, investigators, and advocacy leaders, which helps build trust around Vyjuvek, its first approved product. That work supports evidence sharing, publication planning, and congress presence before and after approval, a must in a rare-disease market with limited patient pools.
- Builds trust with key opinion leaders.
- Supports publications and congress data.
- Helps sustain adoption after approval.
Safety and long-term monitoring
Krystal Biotech, Inc. builds this relationship on ongoing safety tracking, because gene therapy needs long follow-up for adverse events, durability, and repeat-dose use. The FDA’s gene-therapy guidance can require up to 15 years of follow-up, so post-treatment monitoring is part of the product experience, not just the trial phase.
- Track adverse events over years
- Measure durability after each dose
- Watch repeat-dose response closely
- Support long-term gene-therapy follow-up
Krystal Biotech’s Hands-On Care Model Fuels Vyjuvek Support
Krystal Biotech, Inc. keeps Customer Relationships highly hands-on: dermatologists, wound-care teams, and caregivers need dosing, wound-care, and safety support for Vyjuvek, a rare-disease therapy studied in 31 patients. The company also relies on medical affairs and long follow-up, since gene-therapy monitoring can run up to 15 years.
| Relationship | Why it matters | Data point |
|---|---|---|
| Physician support | Prescribing and monitoring | 31-patient pivotal program |
| Caregiver education | Dosing and wound care | Rare disease: under 200,000 U.S. patients |
| Long-term follow-up | Safety and durability | Up to 15 years |
Channels
Specialty dermatology clinics
Specialty dermatology clinics are Krystal Biotech, Inc.’s main care point for rare skin diseases, since they handle diagnosis, treatment, and follow-up in one place. For VYJUVEK, the first FDA-approved gene therapy for dystrophic epidermolysis bullosa, these clinics are the core channel to reach both patients and prescribers, and to support repeat treatment visits.
Clinical trial networks
Krystal Biotech, Inc. uses research centers and investigator sites as the core channel for development-stage enrollment, dosing, and data capture, especially while the portfolio is still clinical-stage. In 2025, this network remained key for moving programs through early trials, where site speed and data quality can decide how fast a study reads out.
Medical conferences and publications
Krystal Biotech uses medical conferences and peer-reviewed papers to share clinical data with rare-disease and dermatology experts. With 1 approved product, VYJUVEK, this channel helps build trust, support investigator recruitment, and speed adoption as doctors see the evidence behind the therapy.
Medical affairs and field education
Medical affairs and field education let Krystal Biotech, Inc. reach specialists through direct scientific exchange on Vyjuvek, the company’s one commercial product in 2025. Field teams explain the mechanism, pivotal trial data, and patient selection for patients 6 months and older, which is standard in rare-disease biotech.
- Direct physician education builds trust
- Focuses on trial data and selection
- Fits niche, specialist-led markets
Company website and investor communications
Krystal Biotech, Inc. uses its website and investor updates to share pipeline news, clinical milestones, and company facts with patients, clinicians, and investors. In 2025, the Company had 1 commercial product, VYJUVEK, so these channels matter for a small public biotech that must build trust fast and keep the market informed.
- Shares pipeline and trial updates
- Supports patient, clinician, and investor awareness
Krystal Biotech’s 2025 Growth Runs Through Specialty Clinics
Krystal Biotech, Inc. sells VYJUVEK through specialty dermatology clinics and field medical teams, since rare skin disease care is specialist-led and repeat visits matter. In 2025, the Company still had 1 commercial product, so conferences, papers, and the website stayed key for trust and awareness.
| Channel | 2025 fact |
|---|---|
| Specialty clinics | 1 approved product: VYJUVEK |
Customer Segments
Patients with dystrophic epidermolysis bullosa
Patients with dystrophic epidermolysis bullosa are B-VEC’s lead orphan-disease segment: a very small group, with DEB incidence estimated at about 3.3 per million live births, facing chronic wounds, pain, and heavy wound-care needs. This is Krystal Biotech, Inc.’s clearest near-term clinical market, with B-VEC approved in the United States since 2023 and in Europe since 2024.
Patients with autosomal recessive congenital ichthyosis
KB105 targets patients with autosomal recessive congenital ichthyosis, a rare inherited skin disorder with an estimated prevalence of about 1 in 200,000 to 1 in 300,000 births. The segment is tiny but clinically important because patients face lifelong scaling, pain, and infection risk, with few approved treatment options and high unmet need.
Patients with Netherton syndrome
Patients with Netherton syndrome are a core orphan-skin-disease segment for Krystal Biotech, Inc. because KB104 is being developed for this ultra-rare disorder, which is marked by severe skin barrier defects, recurrent infections, and high unmet need; published estimates put prevalence at about 1 in 200,000 births. This fits Krystal Biotech, Inc.’s focus on genetically defined dermatology where even small patient pools can support high-value therapies.
Patients with cystic fibrosis
Patients with cystic fibrosis are a larger, broader target than Krystal Biotech, Inc.'s core rare dermatology base, and KB407 moves the platform into a non-skin indication. Cystic fibrosis affects about 40,000 people in the United States and roughly 105,000 worldwide, so even modest adoption could add a meaningful new revenue pool.
- KB407 expands beyond skin disease.
- CF offers a bigger patient base.
- It adds portfolio diversification.
Dermatologists, pediatric specialists, and caregivers
Krystal Biotech, Inc. sells to dermatologists and pediatric specialists who diagnose, prescribe, and track Vyjuvek for dystrophic epidermolysis bullosa, a rare disease seen in about 1 in 20,000 births. Caregivers are the daily users, especially because treatment is approved for patients 6 months and older, so education, access, and support drive use and adherence.
- Dermatologists: diagnosis and prescribing
- Pediatric specialists: early care and monitoring
- Caregivers: daily treatment execution
- Key need: access and support services
Krystal Biotech Targets Ultra-Rare Diseases with High-Need Patients
Krystal Biotech, Inc. serves a very small but high-need base: DEB patients for Vyjuvek, plus ultra-rare ARCI, Netherton syndrome, and cystic fibrosis patients through pipeline programs. The core buying unit is dermatologists and pediatric specialists, while caregivers carry out daily treatment.
| Segment | Need | Scale |
|---|---|---|
| DEB | Wound care | ~3.3/million births |
| ARCI | Skin scaling | ~1:200k-300k births |
| CF | Broader lung need | ~40k U.S.; 105k global |
Cost Structure
Clinical trial spending
Clinical trial spending is a major cost for Krystal Biotech, Inc., with Phase I/II/III work needing sites, monitoring, data management, and patient support. Rare-disease trials are especially pricey because the patient pool is tiny, yet about 300 million people live with rare diseases worldwide, so recruiting and logistics can drive R&D spend to one of the biggest line items.
Research and discovery expenses
Krystal Biotech’s research and discovery spend funds preclinical work, candidate selection, and platform upgrades, including lab studies, assay development, and translational research. In FY2024, research and development expense was about $93 million, supporting pipeline expansion beyond VYJUVEK and future gene-therapy assets.
Manufacturing and CMC costs
Krystal Biotech's manufacturing and CMC costs are heavy because GMP production, quality control, stability testing, and process validation must support every clinical batch and future commercial lot. That matters in a gene-therapy model, where CMC execution can decide whether supply is reliable, scalable, and ready for launch.
Regulatory and compliance costs
Krystal Biotech, Inc. bears ongoing regulatory and compliance spend from IND filings, safety reports, study records, and FDA inspections; INDs are typically reviewed in 30 days, while serious safety events can require reporting within 7 to 15 days. The load is continuous across active programs, and it usually rises as assets move into later-stage trials and more document-heavy oversight.
- INDs need 30-day FDA review
- Safety reports can be 7 to 15 days
- More programs mean more filings
- Late-stage work adds inspection risk
G&A, IP, and talent costs
Krystal Biotech, Inc. keeps a fixed-cost base in G&A, IP, and talent: public-company reporting, legal, finance, and admin work run every quarter, while patent filing and maintenance protect the Vyjuvek franchise and its gene-therapy pipeline. Scientific headcount is also sticky, so payroll, benefits, and stock-based pay stay core cash uses.
For a biopharma business model, this means talent and intellectual property are not optional; they are the operating moat and the main overhead line items.
- Public-company overhead is recurring.
- Patent upkeep protects core assets.
- Scientific headcount is a fixed commitment.
- Legal, finance, admin costs keep repeating.
Krystal Biotech’s R&D-Led Cost Base Runs About $93M in FY2024
Krystal Biotech, Inc.'s cost structure is R&D-led: FY2024 research and development expense was about $93 million, driven by clinical trials, preclinical work, and platform upgrades. Manufacturing, CMC, regulatory filings, IP upkeep, and public-company G&A stay recurring, while scientific headcount and benefits remain a fixed cash use.
| Cost area | FY2024 |
|---|---|
| R&D expense | ~$93 million |
| Core drivers | Trials, CMC, IP, G&A |
Revenue Streams
Future product sales of B-VEC
If approved and commercialized, B-VEC is Krystal Biotech, Inc.’s main revenue engine: sales come from treating dystrophic epidermolysis bullosa, the clearest path to monetize its lead asset. In 2024, Krystal Biotech, Inc. reported about $341.2 million in net product revenue, showing how tightly revenue is tied to B-VEC uptake.
Future product sales from KB105 and KB301
KB105 and KB301 are still development-stage, so they do not yet contribute product revenue as of 2026. If both succeed, KB105 could open a rare genetic skin-disease market and KB301 could add an aesthetics stream, widening Krystal Biotech, Inc.'s commercial base beyond its current approved product sales.
Pipeline sales from KB407 and KB104
KB407 and KB104 are potential new product revenue streams if later-stage data in cystic fibrosis or Netherton syndrome support approval. They would extend Krystal Biotech, Inc. beyond skin disease alone, adding higher-value pipeline optionality on top of its 2025 dermatology base.
Milestone and collaboration payments
Krystal Biotech, Inc. can use milestone and collaboration payments from biotech partners when a program hits development or regulatory steps, such as IND, Phase 2, or approval. This is common in platform drug development and can fund R&D before product sales scale, which matters while Vyjuvek remains the main cash engine.
- Development milestones fund R&D
- Regulatory wins trigger cash
- Partner deals reduce dilution
Licensing and royalty income
Krystal Biotech, Inc. can license its gene therapy platform in selected markets or indications, then collect royalties if partners commercialize those assets. It is a standard non-dilutive biotech stream, and it can scale without adding shares; in 2025, though, Krystal’s revenue was still driven mainly by VYJUVEK sales, so licensing is an upside layer, not the base case.
- Non-dilutive, margin-light income
- Upside grows with partner sales
- Best fit for niche geographies
VYJUVEK Drives Krystal Biotech’s Revenue, With Pipeline Upside Still Ahead
Krystal Biotech, Inc.’s revenue is still dominated by VYJUVEK sales: 2024 net product revenue was about $341.2 million, and that remains the core cash stream into 2026. Milestones and licensing can add non-dilutive cash, but they are secondary until KB105, KB301, KB407, or KB104 reach approval.
| Stream | 2024/2026 status |
|---|---|
| VYJUVEK | Primary revenue |
| Pipeline assets | No product revenue yet |
| Milestones/licensing | Upside cash only |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.